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Key messages
 ► Can data on efficacy and safety of indwelling pleu-
ral catheters (IPC) in malignant pleural effusions be 
extrapolated on patients with non- malignant pleural 
effusions, where the data basis is weak?
 ► Providing adequate symptom control in >90% of pa-
tients with no need for subsequent interventions, IPC 
can be used as a first- line treatment option, where 
disease- specific treatments are exhausted.
 ► We provide a comprehensive overview on patients 
with mainly chronic heart failure and hepatic hydro-
thorax, discuss predictors for pleurodesis and iden-
tify patients with liver cirrhosis to be at high risk for 
complications.
AbstrAct
background Recurrent pleural effusion is a common 
cause of dyspnoea, cough and chest pain during the 
course of infectious pleurisy and non- malignant diseases 
like congestive heart failure (CHF) or liver cirrhosis with 
hepatic hydrothorax (HH). With regard to the chronic 
character of the underlying diseases, indwelling pleural 
catheters (IPC) are increasingly used, not only assuring 
immediate symptom relief but also potentially leading to 
pleurodesis without sclerosing agents.
Patients and methods In this single- centre retrospective 
observational study, patient characteristics, procedural 
variables and outcome in patients with IPC in non- 
malignant pleural effusion (NMPE) were evaluated and 
prognostic factors for pleurodesis were identified.
results From 2006 to 2017, 54 patients received 62 IPC, 
of whom 48.4% with CHF and 43.5% with HH. The median 
length of insertion was 1.5 months (IQR 0.6–2.9 months), 
the median survival time after insertion 3.2 months (IQR 
1.1–16.0). An adequate symptom relief was achieved 
in 93.2% with no need for subsequent interventions. In 
patients surviving ≥30 days after IPC insertion, pleurodesis 
was observed in 45.9%, being associated to age (<55 
years, p=0.02), the primary diagnosis (p=0.03) and 
interventions for the underlying disease (p<0.001). 
Complications occurred in 24.2% of all procedures (n=15), 
the majority concerning mechanical obstructions (n=10) 
and infections (n=4). Patients with HH had an excess risk 
for complications (37.3%).
conclusion Efficacy in symptom relief and a generally 
manageable safety profile recommend IPC as a first- 
line treatment option in NMPE, where disease- specific 
treatments are exhausted. Caution is warranted in patients 
with HH due to an excess risk for complications.
IntroductIon
Chronic and recurrent pleural effusion (PE) 
is a common cause of dyspnoea, cough and 
chest pain affecting 1.5 million patients per 
year in the USA.1 The most common non- 
malignant causes are infectious effusions, 
congestive heart failure (CHF), liver cirrhosis 
resulting in a hepatic hydrothorax (HH) 
and renal failure.2 Although 70%–80% of all 
PEs are non- malignant (NMPE), treatment 
modalities in NMPE are widely adopted from 
the management of malignant PEs.1 Given a 
progressive deterioration of the underlying 
disease with effusion recurrences for years, 
therapeutic approaches should primarily 
focus on causative non- invasive procedures to 
minimise the risk for intervention- associated 
complications like pneumothorax, infections 
or bleeding. In malignant PE, a Cochrane 
network meta- analysis from 2016 considered 
indwelling pleural catheters (IPC) as alterna-
tive first- line therapeutic option besides talc 
pleurodesis (TP).3 The IPC is placed percuta-
neously and the procedure can be performed 
in an outpatient setting.4 Although the 
primary objective is symptom relief, pleu-
rodesis in the absence of any sclerosing agent 
occurs in approximately 50%.5 Notably, for 
NMPE according recommendations are 
lacking as the respective data basis is weak.
The purpose of the present study was to add 
to the existing literature by evaluating clin-
ical outcomes with IPC in NMPE in a single 
institution. Secondary goals were to assess 
survival outcomes in relation to patients and 
clinical variables and to determine predictors 
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of pleurodesis, thus helping physicians to better guide 
clinical care.
PAtIents And methods
For this retrospective single- centre study, patients who 
received an IPC due to symptomatic recurrent NMPE 
treated at the Department of Infectious Diseases and 
Respiratory Medicine at the Charité – Universitätsmedizin 
Berlin were identified using a departmental database and 
the hospital’s clinical reporting system. Data on patient’s 
baseline demographics, underlying disease, quality of 
PE, catheter laterality, pleurodesis, complications, time 
of catheter removal, need of subsequent procedures and 
day of last follow- up or death were collected.
All catheters (PleurX, CareFusion, San Diego, Cali-
fornia, USA) were placed bedside in the endoscopy unit, 
ultrasound- guided and under local anaesthesia by a pulm-
onologist. Prophylactic peri- interventional antibiotics 
were not routinely administered. Outpatient drainage 
was performed by either the patients themselves or an 
ambulatory care service. According to the local standard 
of care, gravity bags were employed rather than vacuum 
bottles. They are generally used in Germany assuring 
slow and comfortable drainage. Patients were instructed 
to connect a gravity bag daily until the fluid accumulation 
decreased to less than 200 mL in 24 hours. Pleurodesis 
was assumed in the presence of less than 200 mL of PE 
per week and was defined as successful if no further inter-
vention was needed after catheter removal. All complica-
tions were graded using the Clavien- Dindo classification 
for surgical complications. Thus, grade I/II complica-
tions only require pharmacological, grade III surgical, 
endoscopic or radiological interventions. Grade IV is life- 
threatening, grade V denotes a procedure- related death.6
Follow- up data were obtained from the departmental 
clinical database and practitioners. Lost to follow- up 
was defined as missing data ≥30 days between last docu-
mented visit and death. Overall survival was defined as 
the interval in months between IPC insertion and death.
PAtIent And PublIc Involvement
As this was a retrospective study, research was done 
without patient involvement. Patients were not invited 
to comment on the study design and were not consulted 
to develop patient relevant outcomes or interpret the 
results. Patients were not invited to contribute to the 
writing or editing of this document for readability or 
accuracy.
stAtIstIcAl AnAlysIs
Demographics and disease data were described and 
compared using the Pearson X2 test, Fisher’s exact test 
or Mann- Whitney- U- test, according to the level of meas-
urement. Binary logistic regression analyses were used 
to identify factors associated with pleurodesis. Survival 
was assessed with the Kaplan- Meier method. P values 
comparing survival curves were calculated with log- rank 
tests. All analyses were performed using IBM SPSS statis-
tics V.24 (IBM). A p<0.05 (two tailed) was defined as 
statistically significant.
results
Between 2006 and 2017, 54 patients received 62 IPC. 
Thirty- two patients were male (59.3%) and 22 female 
(40.7%). Median age at time of catheter insertion was 
68.5 years (range 32–95, IQR 56–76). The most frequent 
diagnoses were CHF (n=30, 48.4%) and liver cirrhosis 
(n=27, 43.5%). Recurrent postinfectious effusions were 
treated with an IPC in three patients. The remaining two 
cases were a chylothorax and one PE of unknown origin. 
All procedures were preceded by at least two thoracen-
teses or a chest tube before insertion of the IPC. Supply 
with an IPC following TP failure was performed in four 
patients (6.5%). More catheters were placed right than 
left sided (62.9 vs 25.8%), in 11.3% bilateral procedures 
were executed. All effusions due to heart failure and 
cirrhosis were transudates, but significant differences 
between those two entities in albumin/protein content 
and serum LDH were noted (albumin 14.1±5.9 g/
dL vs 7.6±6.2 g/dL, p=0.001; protein 25.2±10.1 g/dL 
vs 14.6±10.3 g/dL, p<0.001; LDH 124.3±58.2 U/L vs 
93.1±38.6 U/L, p=0.027). In contrast, all postinfectious 
effusions were exudates. All baseline demographics are 
shown in table 1.
Follow-uP
Median follow- up for all patients was 3.2 months (range 
5 days to 76.5 months, IQR 0.9–12.5). At the time of 
data cut- off (27 March 2018), 10 patients were still alive 
(18.5%), 43 had died (79.6%), one was lost to follow- up 
(1.9%). Considering that most IPCs in NMPE are used as 
palliative treatment for advanced disease states, survival 
after catheter insertion is limited. In the present investi-
gation, 24.1% of patients died within 1 month postproce-
dure (n=13). Nevertheless, the health status of eight 
patients significantly improved after IPC placement and 
they were thus able to receive further interventions for 
their underlying disease (12.9%). Out of seven patients 
with HH, one patient subsequently underwent liver trans-
plantation, six patients received a transjugular intrahe-
patic portosystemic shunt (TIPS), one patient with CHF 
had a transcatheter aortic valve replacement. All proce-
dures were performed within 1 month after IPC place-
ment. Median catheter permanence was 1.5 months for 
all patients (range 5 days to 16.0 months, IQR 0.6–2.9) 
and 2.1 months in those surviving at least 1 month (40 
patients, 47 IPC, IQR 1.5–3.4, p<0.001).
eFFIcAcy And PleurodesIs
To determine the efficacy with regard to sufficient 
symptom relief, we investigated the need of subsequent 
invasive procedures. Follow- up data were available for 
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Table 1 Baseline characteristics
N %
Total 54
  Male 32 59.3
  Female 22 40.7
  Age (years)* 68.5 32–95
Underlying disease
  Heart failure 30 48.4
  Cirrhosis 27 43.5
  Other 5 9.3
  Postinfectious 3 5.6
  Para- pneumonic 2 3.7
  Postperitonitis * 1.9
  Chylothorax * 1.9
  PE of unknown origin * 1.9
Catheters
  Total 62
  Laterality
  Left 16 25.8
  Right 39 62.9
  Bilateral 7 11.3
PE
  Transudate 59 95.2
  Exudate 3 4.8
*Values are given as ‘median (range)’.
PE, pleural effusion.
59 procedures demonstrating no need for additional 
interventions in 93.2% (55/59). Thoracenteses or 
the insertion of a second chest tube after IPC removal 
were performed four times (4/59, 6.8%), of which 
three (5.1%) and one (1.7%) were interventions due 
to a preceding IPC- related complication or pleurodesis 
failure, respectively. Although pleurodesis is not the 
primary goal of IPC, it is associated with improved quality 
of life and therefore indicative of palliation.7 Pleurodesis 
was achieved in 39.0% (23/59; no pleurodesis: 56.5%, 
35/59; not reported: 6.8%, 4/59). All patients with post-
infectious effusions developed pleurodesis, whereas rates 
in cardiogenic effusions and cirrhosis were considerably 
lower (24.1% and 21.1%, respectively, p=0.026). If further 
disease- specific interventions were performed, IPCs were 
able to be removed in 26.7% in heart failure (p NS) and 
40.7% in HH (p=0.009), representing either pleurodesis 
or cessation of pleural fluid accumulation. Median time to 
pleurodesis was 1.6 months (range 16 days to 3.5 months, 
IQR 0.9–3.2). To exclude the negative bias of patients not 
surviving long enough to develop pleurodesis, we further 
examined the subgroup of patients surviving ≥1 month. 
Here, pleurodesis rate increased to 45.9% (17/37 IPC). 
Following pleurodesis, all catheters were removed soon 
(median 0 days, range 0 days to 1.2 months).
PredIctors For PleurodesIs
In univariate logistic regression, age <55 years (p=0.02), 
survival of ≥1 month after IPC insertion (<0.001), the 
primary diagnosis (p=0.03) and interventions for the 
underlying disease (p<0.001) were significantly corre-
lated to pleurodesis. In multiple regression analysis, age 
<55 years (p=0.021, HR 7.14, 95% CI 1.35 to 33.3) and 
interventions for the underlying disease (p=0.009, HR 
16.7, 95% CI 2.08 to 99.8) remained predictive for pleu-
rodesis. No associations were found for catheter perma-
nence, laterality (left vs right, unilateral vs bilateral), 
composition of PE (albumin, protein, LDH) and compli-
cations (yes vs no). Excluding patients who had received 
disease- specific interventions, the primary diagnosis was 
also predictive for pleurodesis (postinfectious effusions 
vs other, p=0.028, HR 17.33, 95% CI 1.35 to 222.16).
comPlIcAtIons
Complications occurred in 24.2% of all procedures 
affecting 20.4% of the patients (15 cases, 11 patients, all 
listed in table 2).
The complication rate was 16.7% (n=5) in heart 
failure and 37.3% (n=10) in cirrhosis (p=0.038). No 
complications were seen in postinfectious PE. The most 
common complications were malfunctions of the IPC 
(66.7%, 10/15), followed by infections (26.7%, 4/15). 
All dislodgements and infections except one occurred in 
patients with cirrhosis. One postinterventional bleeding 
was also seen in this group. Using the Clavien- Dindo 
classification, 86.7% (13/15) were graded as mild or 
moderate. Two fatal complications were seen in patients 
developing empyema with subsequent sepsis and multi-
organ failure. Median time to complication was 19 days 
(range 1–446 days, IQR 10–61). A trend to an earlier 
onset was seen in cirrhosis (27.7 vs 122.4 days in heart 
failure, p=0.14) and with mechanical complications 
(27.5 vs 146.5 days, p=0.075). In general, catheters were 
removed after onset of complications (86.7%, 13/15). 
This concerned all catheters with infections and 9/10 
IPC with mechanical complications. According to the 
Clavien- Dindo classification, removal is considered as an 
intervention and therefore classified as grade III. Micro-
biological cultures were positive in all empyema cases 
(one case each with coagulase- negative staphylococci, Klebsi-
ella pneumoniae and Escherichia coli). One occlusion could 
be resolved using fibrinolytic agents, one bleeding in the 
subcutaneous tract in a patient with liver cirrhosis was 
stopped after local ingestion of epinephrine.
survIvAl wIth IPc
For the entire cohort, median survival after catheter 
insertion was 3.2 months (IQR 1.1–16.0, 95% CI 1.5 to 
4.9). No significant differences were observed for the 
underlying disease with 3.1 months in heart failure (IQR 
1.1–15.3, 95% CI 0.9 to 5.3), 4.0 months in cirrhosis 
(IQR 0.6–42.7, 95% CI 1.8 to 6.2) and 3.2 months in the 





















Total 15 100.0 24.2 2 11 2 19 (1–446)
Aetiology
  Infections 4 26.7 6.5 – 2 2
  Local infection (cellulitis/exit site) 1 6.7 1.6 – 1 –
  Deep infection (empyema) 3 20.0 4.8 – 1 2
  Catheter malfunction 10 66.7 16.1 1 9 –
  Occlusion/mechanical obstruction 2 13.3 3.2 1 1 –
  Dislodgement 5 33.3 8.1 – 5 –
  Leakage 3 20.0 4.8 – 3 –
  Bleeding 1 6.7 1.6 1 – –
Catheter removed 13 86.7 21.0
remaining diseases (IQR 1.8–19.9, 95% CI 0.3 to 6.1, 
p=0.58).
dIscussIon
Recurrent PE is associated with a high disease burden in 
many non- malignant diseases, often indicating the final 
common pathway for these patients without leaving a 
causative treatment option. We here have reported on a 
large single- centre experience on clinical characteristics 
and outcome of patients with IPC in NMPE. Although 
NMPEs are more common than MPE, evidence on IPC in 
NMPE is limited. In a meta- analysis including 325 patients 
from 13 studies, the median number of patients (and 
catheters) per study was only 23 (range 5–57)5 and thus 
lower than the number of patients in studies with MPE 
(median 55, range 5–263).8 The patient distribution in 
our cohort underlines the predominance of patients with 
CHF and HH with the use of IPCs for refractory NMPE 
despite optimal medical therapy and is in line with a 
meta- analysis by Patil et al.5
The primary goal of symptom control and satisfying 
palliation without need for subsequent procedures with 
IPC can be achieved in over 80%.9 Patient satisfaction is 
high, not least because readmission rates substantially 
decrease after catheter insertion.10–12 Furthermore, 
in a study comparing IPC and TP in a propensity- 
matched design, not only the time spent in hospital 
peri- interventionally was shorter with IPC, but also read-
mission rates the year after were lower.13 Due to the retro-
spective character of our study, palliation could only be 
assessed in an indirect manner focusing on the need of 
additional (invasive) procedures like thoracenteses or 
(second) chest tubes. In our study, additional procedures 
were necessary in 6.8% of all catheters, thereby under-
lining the long- term efficacy of the procedure.
Pleurodesis is a convenient side effect of IPC and 
occurs in approximately half of the patients irrespective 
of the underlying disease.5 In our cohort, the general 
pleurodesis rate was 39.0%, but with regard to a median 
time to pleurodesis of 1 month, rates increased to 45.9% 
in those surviving at least this period. As all patients with 
infectious pleurisy developed pleurodesis, the rates were 
substantially driven by this group and were considerably 
lower in CHF (24.1%) and HH (21.1%). The identified 
predictors for pleurodesis included the primary diag-
nosis and the possibility for an interventional approach. 
Thus, in patients with HH, TIPSS implantation and liver 
transplantation augmented pleurodesis rates from 21.1% 
to 40.7%. Li et al recently reported an overall pleurod-
esis rate of 74% using IPC in NMPE.14 Although results 
were influenced by high pleurodesis rates in inflamma-
tory pleurisy and parapneumonic effusions, the reported 
pleurodesis rates in heart and liver failure also were 
substantially higher as compared with our study. Selec-
tion bias could explain this gap, but procedure- related 
differences like the drainage interval applied might also 
play a role, as clearly shown in malignant PE.15 16 Interest-
ingly, despite using a daily drainage interval in our study, 
the pleurodesis rate was inferior to the investigation from 
Li et al using a 2- day regimen. So, to elucidate the value 
of the drainage strategy in NMPE, further prospective 
studies are needed. The exact way how IPC lead to pleu-
rodesis is unclear, however, mechanical irritation causing 
local inflammation likely contributes to it.17 As the inflam-
matory response diminishes with increasing age and is 
altered in liver cirrhosis, older patients and those with an 
HH18 might experience pleurodesis less often, as shown 
in the current study. A general inflammatory condition in 
infectious pleurisy may also provide the rationale for the 
high pleurodesis rates observed.19
In two meta- analyses, (median) rates of periprocedural 
and long- time complications with IPC were slightly higher 
in NMPE than in MPE (17.25 vs 12.5%).8 As most studies 
in NMPE did not report the catheter permanence, one 
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can refer to the longer time to pleurodesis in NMPE (and 
thus longer catheter permanence) as a surrogate for this 
period (36 vs 110 days20). Thus, complication rates in 
both entities seem quite comparable. The most common 
complications are infections and mechanical catheter 
problems. Rates of pleural infections are generally very 
low ranging below 6%,10–13 18 20 except for patients with 
liver cirrhosis and HH, where rates up to 16.7% have been 
described.21 As deep infections usually occur not earlier 
than 6 weeks after the procedure, ingestion of bacteria 
during catheter insertion is unlikely. The higher overall 
complication rate in our study of 24.2% compared with 
17.2% in the meta- analysis by Patil et al5 might be related 
to the longer observation period in our study. Further-
more, 66.7% of all complications occurred within the first 
4 years. In line with the literature, we observed an excess 
risk for complications in patients with HH, comprising 
both mechanical and infectious complications. Thus, the 
use of an IPC in this setting requires close monitoring, 
should be embedded in a multidisciplinary approach and 
requires preventive measures such as patient education 
in the proper use of the catheter.
Due to the retrospective character, the present study 
has several limitations. On the one hand, the data provide 
a deep insight into the management and follow- up of 
patients with IPC in NMPE, even though our data set 
is dominated by patients with CHF and HH and lacks 
patients with, for example, chronic renal failure or rheu-
matic diseases. On the other hand, providing a patient 
with an IPC or not is subject to the physician’s decision 
and thereby source of a selection bias. Symptom- related 
data were not collected regularly; thus, symptom relief 
could only be assessed indirectly with regard to the 
need of subsequent invasive procedures. Moreover, the 
estimation of procedure- related complications may be 
too low as some events may have been undocumented, 
especially in those lost to follow- up. Finally, in patients 
who have received an intervention for the underlying 
disease, it is difficult to differentiate between real pleu-
rodesis and only a cessation of effusion accumulation, 
if the organ function of these patients has conditionally 
improved. Nevertheless, the current study contributes to 
the growing body of evidence of IPC as a safe and feasible 
treatment option also in the management of NMPE, with 
the exception of patients with HH, for whom the use of 
an IPC needs critical consideration due to high compli-
cation rates.
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